Cell Cycle Modulation for Acute Kidney Injury Diagnosis and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and treating acute kidney injury (AKI) are inadequate, as they often fail to identify the condition before irreversible damage occurs and lack effective therapeutic modalities beyond supportive measures.
Innovation Solution
The use of compounds that modulate the cell cycle by inducing G0/G1 cell cycle arrest or progression, combined with biomarkers like urinary insulin-like growth factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinase 2 (TIMP-2), to assess and treat AKI, either prophylactically or as a treatment following injurious events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods for detecting AKI are used, then detection is possible, but irreversible damage occurs before detection
Solution Approach 1:
The patent measures urinary biomarkers (TIMP-2, IGFBP7, KIM-1, NGAL) to detect early cellular stress and injury before irreversible damage occurs. This preliminary detection allows intervention at a stage when the kidney can still recover, resolving the contradiction between detection timing and preventing irreversible damage.
2Ease of manufacture
If supportive measures only are used, then treatment is simple, but effective therapeutic modalities are lacking
Solution Approach 1:
The patent administers cell cycle modulating compounds to change the physiological state of renal cells, promoting progression from G0/G1 arrest to active cell cycle phases. This parameter change in cell cycle state provides an effective therapeutic mechanism that goes beyond simple supportive measures while maintaining treatment feasibility.
3Reliability
If cell cycle arrest is induced prophylactically, then protection against AKI is achieved, but treatment complexity increases
Solution Approach 1:
The patent induces cell cycle arrest prophylactically before AKI occurs, then transitions to cell cycle progression therapy after injury. This preliminary protective action, combined with subsequent treatment, achieves reliable protection while the structured protocol manages complexity through clear phase-based intervention.
Data Source
AI summary
It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.